Neurology® Podcast

1) Neurology: Neuroimmunology & Neuroinflammation: Cryptogenic NORSE: Its distinctive clinical features and response to immunotherapy 2) What's Trending: R&F section update with Dr. Roy StrowdThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the December 12, 2017 issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Takahiro Iizuka about his paper on diagnosis and treatment of new-onset refractory status epilepticus (NORSE). In the second part of the podcast, Dr. Jeff Ratliff focuses his interview with Dr. Roy Strowd on a highlighted Clinical Reasoning case from the new "Resident & Fellow Rounds" feature debuting in 2018.DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). Dr. Langer-Gould has received research support from Biogen, Roche, NIH, PCORI, and the National Multiple Sclerosis Society. Dr. Iizuka serves on editorial boards for Current Treatment Options in Neurology and Rinsho Shinkeigaku (Clinical Neurology), and has received research support from Mitsubishi Tanabe Pharma Corporation (MTPS20160504012) and the Japan Epilepsy Research Foundation (JERFTENKAN 17002).Dr. Ratliff has received a speaker honorarium from Haverford College. Dr. Strowd serves on the editorial board of Neurology (Resident & Fellow section); and has received research support from the Wake Forest School of Medicine Center for Translational Sciences Award, the KL2 Career Development Award, and the American Academy of Neurology.

Show description/summary:1) Long-term benefit of enzyme-replacement therapy in Pompe disease: A 5-year prospective study2) What's Trending: ACTH or prednisolone for infantile ataxiaThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the December 5, 2017 issue of Neurology. In the first segment, Dr. Kelly Gwathmey talks with Dr. Nadine van der Beek about her paper on enzyme-replacement therapy in Pompe disease. In the second part of the podcast, Dr. Ted Burns focuses his interview with Dr. John Mytinger on the topic of ACTH or prednisolone for infantile ataxia. DISCLOSURES: Dr. Gwathmey reports no disclosures.Dr. van der Beek has received speaker honoraria from Sanofi-Genzyme (paid to to Erasmus MC for further research purposes); and has received research support from Sanofi-Genzyme, Colciencias, ZonMW - the Netherlands Organization for Health Research and Development, the Prinses Beatrix Spierfonds, SSWO – Sophia Children's Hospital Foundation, and TKI-Health Holland.Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring.Dr. Mytinger reports no disclosures.

This month's Delayed Recall episode is the first in a duo of episodes featuring interviews that focus on the patient perspective. The second part of this feature will appear as the Delayed Recall episode for January 2018. As the first of the three interviews included in December's episode, we feature an interview by Dr. Ted Burns with Dr. Oliver Sacks regarding Dr. Sacks' experience with ocular melanoma. This interview originally aired in January 2011, and appeared again as part of a Delayed Recall episode in 2015, which was aired as a tribute to Dr. Sacks following his passing. In the second interview of this episode, from February 19, 2013, Dr. Burns speaks with Dr. Bob Holloway on communicating prognosis for patients with serious neurological diseases. In the third and final interview in this episode, Dr. Burns speaks with Dr. Richard Morton about his essay regarding his experience as a patient. This interview was part of the July 25, 2017 podcast episode.

1) Midlife systemic inflammatory markers are associated with late-life brain volume: The ARIC study2) What's Trending: Neurology paper on breast feeding, ovulatory years, and risk of multiple sclerosisThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 28, 2017 issue of Neurology In the first segment, Dr. Jeff Burns talks with Dr. Keenan Walker about his paper on the association between systemic inflammation and brain volume over time. For our What's Trending segment, Dr. Stacey Clardy focuses her interview with Dr. Annette Langer-Gould about her recent Neurology article on breast feeding, ovulatory years, and risk of multiple sclerosis.DISCLOSURES: Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001)Dr. Walker has received research support from the National Institute of Aging (AG027668, postdoc fellow, 2016-17).Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).Dr. Langer-Gould has received research support from Biogen, Roche, NIH, PCORI, and the National Multiple Sclerosis Society.

Show description/summary:1) Multiparametric MRI changes persist beyond recovery in concussed adolescent hockey players 2) Neurology Today® paper on the increase in gabapentinoid prescriptionThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 21, 2017 issue of Neurology. In the first segment, Dr. Ted Burns talks with Dr. Kathryn Manning and Dr. Ravi Menon about their paper regarding the effects of concussion on adolescent hockey players. In the second part of the podcast, Dr. Burns focuses his interview with Dr. Christopher Goodman about a recent Neurology Today article discussing the increase in gabapentinoid prescriptions. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring.Dr. Manning reports no disclosures.Dr. Menon has served on the scientific advisory board of International Initiative for Traumatic Brain Injury Research (NIH/EU/CIHR); has served on the editorial boards of NeuroImage, Journal of Neurophysiology, Scientific Reports, and Tomography; has received research support from Siemens Healthineers, Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Canada First Research Excellence Fund, and Brain Canada Foundation; and has received royalty payments from Siemens Healthcare for US Patent 8,193,812.Dr. Goodman reports no disclosures.

Show description/summary:1) Infliximab for the treatment of central nervous system sarcoidosis: A multi-institutional series2) What's Trending: Sonic traumatic brain injuryThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 14, 2017 issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Siddharama Pawate and Dr. Jeff Gelfand about their paper on infliximab for treatment of central nervous system sarcoidosis. In the second part of the podcast, Dr. Alex Menze focuses his interview with Dr. Jeffrey Kim on the recent speculation around sonic traumatic brain injury.DISCLOSURES: Dr. Gelfand has served on scientific advisory boards for Genentech; has received compensation for consulting with Genentech; has received research support from Quest Diagnostics, Genentech, MedDay, and NIH National Center for Advancing Translational Sciences (KL2TR000143); and has received compensation for serving as expert witness in medical-legal consulting. Dr. Pawate has served on scientific advisory board for Biogen, and has received research support from Biogen.Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).All other participants report no disclosures.

Show description/summary:1) This variant alters protein function, but is it pathogenic? (Neurology® Genetics)2) What's Trending: PFO UpdatesThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 7, 2017 issue of Neurology. In the first segment, Dr. Michelle Mauermann talks with Dr. Massimo Pandolfo about his recent Neurology® Genetics editorial, entitled "This variant alters protein function, but is it pathogenic?". In the second part of the podcast, Dr. Nicole Chiota focuses her interview with Dr. Steven Messe on recent PFO/stroke updates. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Mauermann serves on the editorial board of Mayo Clinic Proceedings; receives publishing royalties from Oxford, and has received research support from Ionis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals.Dr. Pandolfo has served on the scientific advisory boards of Apopharma and Voyager Therapeutics; has served on the editorial boards of Acta Neurologica Belgica, Orphanet Journal of Rare Diseases, and Neurology Genetics; is co-holder of a patent for Direct molecular diagnosis of Friedreich's ataxia; has been a consultant for Biomarin and UCB; has received research support from Biomarin, Fonds National de la Recherche Scientifique (Belgium), Offrez-moi-la-lune, Friedreich's Ataxia Research Alliance, and Association Belge contre les Maladies neuro-Musculaires, and receives royalty payments from Athena Diagnositcs for a Friedreich's ataxia diagnostic test.Dr. Chiota reports no disclosures.Dr. Messe has served on the scientific advisory board of the Yale University Cardiovascular Research Group; has received travel funding from the American Academy of Neurology; has received publishing royalties from Up To Date; has been a consultant for Claret Medical; and has received research support from WL Gore, Glaxo Smith Kline, Bayer, Mallinkrodt, and NIH.

This month's Delayed Recall episode features Dr. Stacey Clardy's Lesson of the Week interviews on the topic of immunotherapy, which originally aired in July 2017. In the first interview, Dr. Clardy speaks with Dr. Dennis Bourdette about new immunotherapies in neurology. This interview first appeared in the July 4 episode. In the interview from July 11, Dr. Clardy continues the discussion about new immunotherapies with Dr. Jeffrey Cohen. The third interview, from the July 18 episode, features Dr. Clardy speaking with Dr. Emmanuelle Waubant about immunotherapy as it applies to multiple sclerosis patients. To conclude this episode, we offer Dr. Clardy's interview with Dr. Anne Cross, in which they talk about immunosuppressants in Neurology; this interview was part of the July 25 episode.

Show description/summary:1) Change in multimodal MRI markers predicts dementia risk in cerebral small vessel disease2) What's Trending: dabigatran reversal in patients with uncontrolled bleeding This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 31, 2017, issue of Neurology. In the first segment, Dr. Matthew Elliot talks with Dr. Hugh Markus about his paper multimodal MRI markers and dementia risk in cerebral small vessel disease. In the second part of the podcast, Dr. Bryan Eckerle focuses his interview with Dr. Charles Pollack on dabigatran reversal in patients with uncontrolled bleeding or receiving surgery. DISCLOSURES: Dr. Markus serves as section editor of International Journal of Stroke; serves on the editorial board for Clinical Neurology and Neurosurgery, and BMC Medicine; serves as Associate Editor for Fronteirs in Neurology; receives publishing royalties from Stroke Medicine (OUP 2016); has consulted and led a teaching session for Astra Zeneca; and has received research support from MRC, NIHR, Stroke Association, EU, Wellcome Trust, The British Heart Foundation, and Alzheimer Research UK. Dr. Eckerle and Dr. Elliot report no disclosures.Dr. Pollack has received research support from Boehringer Ingelheim, Daiichi Sankyo, CSL Behring, Janssen Pharma, AstraZeneca, and Portola; and has served as scientific consultant for Boehringer Ingelheim, BMS/Pfizer, Janssen Pharma, AstraZeneca, and Portola.

Show description/summary:1) Persistent focal enhancement of the cisternal segment of oculomotor nerve in ophthalmoplegic migraine (Neurology® Clinical Practice)2) What's Trending: Tenecteplase for acute ischemic strokeThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 24, 2017 issue of Neurology. In the first segment, Dr. Heather Harle talks with Dr. Ihtesham Qureshi about his Neurology® Clinical Practice paper on ophthalmoplegic migraine. In the second part of the podcast, Dr. Justin Sattin focuses his interview with Dr. Nicola Logalio on using tenecteplase for acute ischemic stroke. Disclosures can be found at Neurology.org.DISCLOSURES: All participants report no disclosures.